Dr. Palumbo on CASTOR Trial Results in Multiple Myeloma

Antonio Palumbo, MD
Published: Sunday, Jun 05, 2016

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

In this study, the primary endpoint was progression-free survival. Results showed that the addition of daratumumab reduced the risk of disease progression by 61%, Palumbo says.

Additionally, there were major increases in response rates in patients who received the triplet regimen. The complete response rate was doubled from 9% to 19%, while the rate of very good partial response was doubled from 29% to 59%. This demonstrates that the 3-drug therapy should be considered the standard of care for these patients, he explains.

<<< View more from the 2016 ASCO Annual Meeting

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

In this study, the primary endpoint was progression-free survival. Results showed that the addition of daratumumab reduced the risk of disease progression by 61%, Palumbo says.

Additionally, there were major increases in response rates in patients who received the triplet regimen. The complete response rate was doubled from 9% to 19%, while the rate of very good partial response was doubled from 29% to 59%. This demonstrates that the 3-drug therapy should be considered the standard of care for these patients, he explains.

<<< View more from the 2016 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x